Clinical Trial Update: Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007) [Phase 3]

View source ↗

Summary

Phase 3 extension trial of esmirtazapine (ORG 50081) in outpatients with chronic primary insomnia; trial terminated with posted results in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Org 50081

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Sleep Initiation and Maintenance Disorders, Mental Disorders | Phase 3 | Status: TERMINATED | Results posted: 2014-06-24